Last edition
News about Global Pharma
Veranova Names Thomas Rohrer as Vice President of Bioconjugation
Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation.
Global Pharma | 29/07/2025 | By Dineshwori | 283
Dr. Reddy's Injects INR 565 Crore into Russian Arm
Dr Reddy’s Laboratories Ltd has invested INR 565.4 crore in its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19 percent equity stake in the step-down wholly-owned subsidiary.
Global Pharma | 29/07/2025 | By Dineshwori | 750
PTC Therapeutics Secures US FDA Approval for SEPHIENCE
PTC Therapeutics has received FDA approval for SEPHIENCE (sepiapterin) to treat sepiapterin-responsive phenylketonuria (PKU) in patients aged one month and older, offering a new therapy for managing this rare metabolic disorder.
Global Pharma | 29/07/2025 | By Mrinmoy Dey | 358
Kinvard Bio has secured USD 2.7 million in follow-on non-dilutive funding from CARB-X to advance its novel ribosome-targeting antibiotics toward preclinical development, tackling drug-resistant infections like MRSA and cUTI.
Global Pharma | 29/07/2025 | By Mrinmoy Dey | 207
AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion
For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.
Global Pharma | 29/07/2025 | By Dineshwori | 332
Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns
Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.
Global Pharma | 28/07/2025 | By Dineshwori | 896
Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.
Global Pharma | 28/07/2025 | By Mrinmoy Dey | 355
Elpis Biopharmaceuticals has signed an MoU with the National Cancer Centre Singapore. The collaboration focuses on advancing clinically validated armoured CAR technologies into first-in-human trials in Singapore and accelerating translational research from bench-to-bedside.
Global Pharma | 28/07/2025 | By Mrinmoy Dey | 291
AstraZeneca's Imfinzi Granted Priority Review by FDA for Early-Stage Gastric and GEJ Cancers
The US Food and Drug Administration (FDA) has accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) and granted Priority Review for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Global Pharma | 28/07/2025 | By Dineshwori | 198
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
Global Pharma | 28/07/2025 | By Dineshwori | 273
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy